Amygdala-enriched genes identified by microarray technology are restricted to specific amygdaloid subnuclei
Abstract
Microarray technology represents a potentially powerful method for identifying cell type- and regionally restricted genes expressed in the brain. Here we have combined a microarray analysis of differential gene expression among five selected brain regions, including the amygdala, cerebellum, hippocampus, olfactory bulb, and periaqueductal gray, with in situ hybridization. On average, 0.3% of the 34,000 genes interrogated were highly enriched in each of the five regions, relative to the others. In situ hybridization performed on a subset of amygdala-enriched genes confirmed in most cases the overall region-specificity predicted by the microarray data and identified additional sites of brain expression not examined on the microarrays. Strikingly, the majority of these genes exhibited boundaries of expression within the amygdala corresponding to cytoarchitectonically defined subnuclei. These results define a unique set of molecular markers for amygdaloid subnuclei and provide tools to genetically dissect their functional roles in different emotional behaviors.
Additional Information
© 2001 by the National Academy of Sciences. Communicated by Giuseppe Attardi, California Institute of Technology, Pasadena, CA, February 26, 2001 (received for review December 7, 2000). Accepted February 26, 2001. We thank R. Mongeau for dissecting the PAG; A. Smith and J. Xiao (Stanford University/Howard Hughes Medical Institute) for performing microarray hybridizations; G. Meissner, C. Hsu, and S. Pintchovski for help with in situ hybridization; G. Miller for help with Fig. 2; and G. Mosconi for managerial assistance. We also acknowledge M. Zylka and B. Wold for helpful discussions. This work was supported by National Institute of Mental Health Grant MH62825, a gift from Merck Inc., and a grant from the Mettler Fund on Autism. D.J.A. is a Howard Hughes Medical Institute Investigator.Attached Files
Published - ZIRpnas01.pdf
Supplemental Material - 0946AppendixA.html
Supplemental Material - 0946AppendixB.html
Supplemental Material - 0946Fig5andLegend.html
Supplemental Material - 0946Table3.html
Supplemental Material - 0946Table4.html
Files
Name | Size | Download all |
---|---|---|
md5:f8250d09605b6084263ffb5f61aad2fd
|
78.2 kB | Download |
md5:0d3a2ed19eabc47b94bd5bbefac41c0d
|
871.0 kB | Download |
md5:1dc08902bda6528d11e20dc19d05f101
|
116.9 kB | Download |
md5:7ed16bb9f2d13395cee6ab02fba426a7
|
2.3 MB | Preview Download |
md5:994ef145d28374c613240a1f3e2f46c1
|
34.6 kB | Download |
md5:821a758ecbd542d996a0243197aa7a1a
|
56.4 kB | Download |
Additional details
- PMCID
- PMC33199
- Eprint ID
- 10079
- Resolver ID
- CaltechAUTHORS:ZIRpnas01
- NIH
- MH62825
- Merck Inc.
- Mettler Fund on Autism
- National Institute of Mental Health (NIMH)
- Created
-
2008-04-10Created from EPrint's datestamp field
- Updated
-
2021-11-08Created from EPrint's last_modified field
- Caltech groups
- Koch Laboratory (KLAB)